GENETICS GENERATION ADVANCEMENT CORP. Genetics Generation Advancement Corp. Stock
Equities
4160
TW0004160007
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.3 TWD | -0.40% |
|
+21.79% | +29.31% |
| Sales 2022 | 548M 16.78M | Sales 2023 | 592M 18.15M | Capitalization | 988M 30.28M |
|---|---|---|---|---|---|
| Net income 2022 | 25M 766K | Net income 2023 | 28M 858K | EV / Sales 2022 | 0.75 x |
| Net cash position 2022 | 255M 7.82M | Net cash position 2023 | 266M 8.14M | EV / Sales 2023 | 1.22 x |
| P/E ratio 2022 |
26.1
x | P/E ratio 2023 |
34.7
x | Employees | 104 |
| Yield 2022 |
1.74% | Yield 2023 |
1.31% | Free-Float | 58.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.40% | ||
| 1 week | +21.79% | ||
| Current month | +18.91% | ||
| 1 month | +17.39% | ||
| 3 months | +20.62% | ||
| 6 months | +34.49% | ||
| Current year | +29.31% |
1 week
40.20
51.40
1 month
40.2051.40
Current year
38.0051.40
1 year
30.6852.40
3 years
21.4752.40
5 years
18.5252.40
10 years
18.5252.40
| Managers | Title | Age | Since |
|---|---|---|---|
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Tai Sheng Chang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fang Chun Huang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Jen Huang
BRD | Director/Board Member | - | 20-06-09 |
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Wen Cheng Chang
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 50.3 | -0.40% | 1,093,370 |
| 24-04-23 | 50.5 | +9.90% | 1,218,704 |
| 24-04-22 | 45.95 | +9.93% | 263,161 |
| 24-04-19 | 41.8 | 0.00% | 36,174 |
| 24-04-18 | 41.8 | +0.12% | 24,766 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
Genetics Generation Advancement Corp is a Taiwan-based company principally engaged in genetic testing business. The Company mainly provides genetic testing, molecular diagnostics, biotechnology, personalized medical related testing, biological information and health care services. The Company mainly serves in the areas of maternal-fetal precision, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection and precision health management. The Company operates its businesses in domestic market and overseas markets.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.31% | 39.38M | |
| -14.52% | 11.53B | |
| +44.03% | 3.31B | |
| -33.09% | 2.11B | |
| -18.60% | 2.05B | |
| -27.59% | 1.49B | |
| +17.10% | 1.02B | |
| -3.06% | 741M | |
| -33.50% | 426M | |
| -46.94% | 374M |
- Stock Market
- Equities
- 4160 Stock
